Elecsys EBV EBNA IgG
Roche Diagnostics · Decision date Oct 2, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 10/02/2026 for Elecsys EBV EBNA IgG, submitted by Roche Diagnostics of Indianapolis, Indiana, under 510(k) number K260221. The application was received 01/26/2026 and reviewed in the Microbiology panel and regulation medical specialty, with classification product code LSE and subsequent product codes LLM and MCD. The device classification name listed is Epstein-Barr Virus, Other, under regulation number 866.3235.
SESE in the 510(k) pathway denotes clearance to market, not premarket approval. The record describes a traditional review not conducted by a third party, and it lists no combination product and no authorized predetermined change control plan. The public record does not include the decision summary text, so the specific device components, comparison predicate, and performance evidence supporting the clearance remain unknown from this source.
The page also lists applicant contact Linda McCammack and correspondent contact Cynthia Aker, with a page last updated date of 10/26/2026. No clinical claims, indications, or analytical performance figures appear in the available material, and none should be inferred from the clearance alone.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Oct 2, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260221
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Roche Diagnostics
- Product code
- LSE
- Decision code
- SESE
- Decision date
- Oct 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Epstein-Barr Virus, Other.
- Applicant
- Roche Diagnostics
- Product code
- LSE
- FDA device class
- 1
FDA decision timeline
K260221 received
Application receipt date recorded by FDA.
K260221 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code LSE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Elecsys EBV VCA IgGK260232 | Roche Diagnostics | 510(k) clearance | Oct 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Diagnostics
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Indianapolis, IN
Sources and methodology
- Original FDA record: K260221
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records